The overarching goal of my laboratory is to systematically investigate the molecular mechanisms of membrane trafficking in cancer progression and to identify actionable targets for cancer therapy. We employed an autochthonous mouse model that develops metastatic lung adenocarcinoma (LUAD) from the expression of mutant K-ras and p53 in the lungs. The mouse model and the derived syngeneic murine LUAD cell lines provide a unique platform to study membrane trafficking that directly correlates to LUAD metastasis. We have identified that the epithelial-to-mesenchymal transition (EMT)-activating transcription factor, ZEB1, initiates a pro-metastatic membrane trafficking program to coordinate cell-intrinsic pathways and immunosuppressive tumor microenvironment (TME) to drive LUAD metastasis. The aberrant membrane trafficking machinery in mesenchymal cancer cells confers a vulnerability of EMT-driven metastatic cancers. Based on the discoveries and preliminary findings, we aim to dissect the EMT-driven pro-metastatic membrane trafficking program and investigate its functions in TME and LUAD progression.
University of Kentucky
Lexington, Kentucky, USA
Toxicology and Cancer Biology
AACR-Aflac, Inc. Scholar-in-Training Awards
American Association for Cancer Research (AACR)
AACR Scholar-in-Training Awards
American Association for Cancer Research (AACR)
A. Lavoy Moore Fellowship in Lung Cancer Research
University of Texas MD Anderson Cancer Center
AACR-June L. Biedler Scholar-in-Training Award
American Association for Cancer Research (AACR)
The NIH Pathway to Independence Award (K99/R00)
NIH/NCI
R00 CA249048
Senior Scientist or Principal Investigator
University of Kentucky, Lexington, USA
01 Aug 2023 - present